TABLE 3.
Percent of patients achieving seroprotection (seroconversion for pertussis antigens) by DTaP-IPV-Hib one month postvaccination (DTaP-IPV-Hib full analysis set)
| Group 1 (MenACYW-D) (n=35 to 53)* | Group 2 (MCC) (n=41 to 54) | Historical controls (n=178 to 218)† | |
|---|---|---|---|
| Diphtheria (≥0.1 IU/mL) | 100 (92.3–100) | 100 (93.4–100) | 99.1 (96.7–99.9) |
| Tetanus (≥0.1 IU/mL) | 100 (92.5–100) | 100 (93.3–100) | 100 (98.3–100) |
| Pertussis booster response‡ | |||
| PT* | 100 (92.0–100) | 94.3 (84.3–98.8) | 96.7 (93.4–98.7) |
| FHA | 97.7 (88.0–99.9) | 88.0 (75.7–95.5) | 83.2 (77.5–87.9) |
| PRN | 92.7 (80.1–98.5) | 78.8 (65.3–88.9) | 86.9 (81.6–91.1) |
| FIM | 100 (91.6–100) | 96.8 (85.7–99.5) | 95.7 (92.1–98.0) |
| PRP-T (≥1 ug/mL) | 100 (92.3–100) | 100 (93.3–100) | 99.1 (96.8–99.9) |
| Poliovirus (≥8 1/dilution) | |||
| Type 1 | 100 (92.3–100) | 100 (92.3–100) | 99.5 (97.5–100) |
| Type 2 | 100 (92.3–100) | 100 (92.7–100) | 99.5 (97.5–100) |
| Type 3 | 100 (92.1–100) | 100 (92.7–100) | 99.5 (97.5–100) |
Data presented as % (95% CI).
Sample size varies depending on usable data;
Data from Grimprel et al (15);
≥2-4-fold (dependent on predose titre) increase in titre. DTaP-IPV-Hib Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed); FHA Filamentous hemagglutinin; FIM Fimbriae; MenACYW-D Quadrivalent meningococcal conjugate vaccine; MCC Meningococcal conjugate serogroup C vaccine; n Values based on all participants available; PRN Pertactin; PRP-T Polyribosylribitol phosphate conjugated to tetanus toxoid; PT Pertussis toxoid